PL BioScience announces Strengthening of Management Team Appointment of Oliver Dick as new Chief Technology Officer PL BioScience announced the strengthening of its management team with the appointment of Oliver Dick, PhD. Oliver Dick joins the team as Chief Technology Officer, a strategic position as the company
First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell
Vero cells are used in the development of Covid-19 vaccines Vero cells are used a lot in research and industry. Time to have a closer look at this cell line: Vero cells are continuous cell lines that was derived from the kidney of an African green monkey
PL BioScience is mentioned in the local newspaper ‘Aachener Zeitung’ one more time. Prior to the award ceremony on 6 June 2019, PL BioScience is presented in the recent press article as one of the five finalists. Our whole team is delighted about the appreciation and innovative strength
PL BioScience in 'Journal of the Chamber of Industry and Commerce Aachen' (Wirtschaftliche Nachrichten der Industrie- und Handelskammer Aachen) As one of the five finalists of the AC² Innovation Award 2019, we were able to present our patent-protected technologies to the Journal. The recent report pictures our novel cell
PL BioScience's technology in the local newspaper 'Aachener Zeitung'. Our platelet-based technology is one out of five 'technologies of the future' nominated for the AC² Innovation Award 2019 which honours one local laureate with unique innovative strength. 'Aachener Zeitung' has just presented the five finalists which have the opportunity
"We demonstrate that human platelet lysate (hPL) can replace hS in macrophage cultivation [
The state-of-the-art workshop on the use of human Platelet Lysate for cell therapy was sponsored by PL BioScience. The meeting took place 22‐23 March 2018 in Zurich (Switzerland). Currently, the summarising Committee Report was published. The main stakeholders in the hPL area focused on the question: 'How can hPL further
New Zealand plans to slaughter 150,000 cows as it tries to eradicate a strain of disease-causing Mycoplasma bovis bacteria. The bacteria was found for the first time in New Zealand in 2017 and can cause cows to develop mastitis, pneumonia, arthritis and other diseases. The impacts on the use and
[embed]https://www.youtube.com/watch?v=STL-rEh9_QQ[/embed] 'What are the remaining challenges in the field of cell culture?' Our CEO Dr. Hatim Hemeda about animal component-free cell culture and market trends. During World Advanced Therapies & Regenerative Medicine Congress 2018 in London, our CEO Hatim spoke to Freya Leask (RegMedNet Editor) about the
PL BioScience is cited on 'LABO ONLINE', the Specialist Portal for analytics, laboratory technology & applications (09 November 2017) (Article only available in German) Textauszüge: "Das humane Blutplättchen-Lysat (hPL) gehört zu den tierserumfreien Nährmedien. [
Interview with our CEO, Dr. Hatim Hemeda, in the Memebers Information Booklet 'Doctors Against Animal Experiments Germany' (Issue 3/2017) (Article only available in German) Textauszug: “Humanes Plattchenlysat ist ein vergleichbar junges Produkt, das erst nach 2013 auf den Markt gekommen ist. […] Es fällt schwer zu glauben, aber
Article in the Memebers Information Booklet 'Doctors Against Animal Experiments Germany' (Issue 3/2017) (Article only available in German) Textauszüge: "Der wichtigste Grund, weshalb auf den Gebrauch von fetalem Kälberserum verzichtet werden sollte, ist, dass die Gewinnung mit erheblichem Leid und dem Tod von Millionen Kälberfeten einhergeht." "Um das millionenfache
PL BioScience is mentioned in the University Newspaper RWTHinsight (Article only available in German) RWTHinsight Issue 01/2016 Photo: Peter Winandy
Interview with our colleague Ute Steinbusch in the issue 3/2016 of the magazine 'Laborjournal' (Article only available in German) Textauszug: "Die Zahl serumfreier Alternativen zum FBS steigt. Ein Start-up aus Aachen beispielsweise bietet humanes Blutplättchenlysat (hPL) als Wachstumsmedium an - auf Wunsch sogar dreidimensional. Ein Gespräch über Zweitverwertung und
